Last Posted: Jan 05, 2017
- All men with metastatic prostate cancer should have genetic testing
KnowRidge, December 29, 2016 - Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.
Hamilton Jada G et al. Journal of general internal medicine 2016 Dec - Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study.
Gray Stacy W et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Dec JCO2016671503 - From genes to therapies -- Systems Medicine of Neuro Endocrine Prostate Cancer - Beyond the Abstract
K Rehman, Uro Today, November 2016 - From genes to therapies -- Systems Medicine of Neuro Endocrine Prostate Cancer - Beyond the Abstract
K Rehman, Uro Today, November 2016 - Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.
Albala David et al. Reviews in urology 2016 18(3) 123-132 - Differences in survival for patients with familial and sporadic cancer.
Lee Myeongjee et al. International journal of cancer 2016 Oct - Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde Emilie et al. European urology 2016 Nov - Should we Perform Genetic Testing on Men with Metastatic Prostate Cancer?
Mikropoulos C et al. Clinical oncology (Royal College of Radiologists (Great Britain)) 2016 Oct - Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Zeichner Simon B et al. Oncology (Williston Park, N.Y.) 2016 Oct 30(10) - Common cancers share familial susceptibility: implications for cancer genetics and counselling.
Yu Hongyao et al. Journal of medical genetics 2016 Sep - A gene defect as a potential gateway for targeted prostate cancer therapy
EMBO News, Sept 2016 - Precision medicine for advanced prostate cancer.
Mullane Stephanie A et al. Current opinion in urology 2016 May 26(3) 231-9 - The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri Christopher E et al. European urology 2016 Aug - The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.
Gaudreau Pierre-Olivier et al. Biomarkers in cancer 2016 8(Suppl 2) 15-33 - Urologists' Current Practices in Screening and Treating Men with a Family History of Prostate Cancer.
Rudichuk Lauren et al. Urology 2016 Sep
From CDC Information Database
This database includes general CDC public health information on specific diseases and health related topics. When available, the database displays genomic information from various CDC web pages. Users are also encouraged to conduct searches of CDC website for additional information.
From CDC-Authored Genomics Publication Database
This database contains CDC-authored publications in public health genomics including infectious diseases, newborn screening, reproductive health, genetic testing, cancer, chronic diseases, birth defects and developmental disabilities, environmental and occupational health as well as laboratory, bioinformatics and statistical methods.
- Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.
Simonds Naoko I et al. J. Natl. Cancer Inst. 2013 Jul 3. 105(13) 929-36
From Guideline Database
This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.
- A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
Published 2015 (American College of Medical Genetics and Genomics) (National Society of Genetic Counselors)
From Tier Table Database
CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.
| Disease/Disorder | Test to be Assessed | Intended Use | Tier Classified | Detail |
|---|---|---|---|---|
| Prostate cancer | Tumor gene expression analysis (Prolaris®, Oncotype Dx® Prostate) | Prognostic, management | Tier 2  |
From HuGE Literature Finder Database
This database contains published literature on genetic associations and other human genome epidemiology
- Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.
Annals of oncology : official journal of the European Society for Medical Oncology 2016 Dec .
Shiota M, Fujimoto N, Itsumi M, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto - Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
European urology 2016 Dec .
Na Rong, Zheng S Lilly, Han Misop, Yu Hongjie, Jiang Deke, Shah Sameep, Ewing Charles M, Zhang Liti, Novakovic Kristian, Petkewicz Jacqueline, Gulukota Kamalakar, Helseth Donald L, Quinn Margo, Humphries Elizabeth, Wiley Kathleen E, Isaacs Sarah D, Wu Yishuo, Liu Xu, Zhang Ning, Wang Chi-Hsiung, Khandekar Janardan, Hulick Peter J, Shevrin Daniel H, Cooney Kathleen A, Shen Zhoujun, Partin Alan W, Carter H Ballentine, Carducci Michael A, Eisenberger Mario A, Denmeade Sam R, McGuire Michael, Walsh Patrick C, Helfand Brian T, Brendler Charles B, Ding Qiang, Xu Jianfeng, Isaacs William - NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.
Oncotarget 2016 Dec .
Fu Wen, Zhuo Zhen-Jian, Chen Yung-Chang, Zhu Jinhong, Zhao Zhang, Jia Wei, Hu Jin-Hua, Fu Kai, Zhu Shi-Bo, He Jing, Liu Guo-Cha - Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.
Oncotarget 2016 Dec .
Wang Mengyun, Li Qiaoxin, Gu Chengyuan, Zhu Yao, Yang Yajun, Wang Jiucun, Jin Li, He Jing, Ye Dingwei, Wei Qing - Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer.
Cancer biomarkers : section A of Disease markers 2016 Dec .
Hashemi Mohammad, Danesh Hiva, Bizhani Fatemeh, Narouie Bahzad, Sotoudeh Mehdi, Nouralizadeh Akbar, Sharifiaghdas Farzaneh, Bahari Gholamreza, Taheri Mohs
.png)
No hay comentarios:
Publicar un comentario